Search

Displaying results 1021 - 1030 of 2817 in total
  1. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.

  2. Drug

    PZ-128

    go.drugbank.com/drugs/DB11839
    Investigational

    PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.

  3. Drug

    HKI-357

    go.drugbank.com/drugs/DB13002
    Investigational

    Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).

  4. Drug

    Cadonilimab

    go.drugbank.com/drugs/DB16680
    Investigational

    Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

  5. Drug

    Tavapadon

    go.drugbank.com/drugs/DB14899
    Investigational

    Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride

    Synonyms: PF-06649751
  6. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Mixtures: 28tak Gum Care Tooth, Dr.EL GUM CARE TOOTH
  7. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896].

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People

  10. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presenc...

    Mixtures: RAMIPRIL HEXAL PL PIR5/6MG, RAMIPRIL HEXAL PL PIR5/6MG